170 related articles for article (PubMed ID: 24671865)
1. The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
Macleod S; Lasko P; Mackenzie A
J Popul Ther Clin Pharmacol; 2014; 21(1):e47-55. PubMed ID: 24671865
[TBL] [Abstract][Full Text] [Related]
2. The role of academic institutions in the development of drugs for rare and neglected diseases.
Coles LD; Cloyd JC
Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
[TBL] [Abstract][Full Text] [Related]
3. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
Roberts EA; Herder M; Hollis A
CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
[No Abstract] [Full Text] [Related]
4. Canada's progress toward an orphan drug framework: 2014.
Lee DK
J Popul Ther Clin Pharmacol; 2014; 21(1):e41. PubMed ID: 24671825
[No Abstract] [Full Text] [Related]
5. Rare diseases: Canada's "research orphans".
Gupta S
Open Med; 2012; 6(1):e23-7. PubMed ID: 22567079
[No Abstract] [Full Text] [Related]
6. Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
Herder M; Krahn TM
Healthc Policy; 2016 May; 11(4):70-81. PubMed ID: 27232238
[TBL] [Abstract][Full Text] [Related]
7. An Orphan Drug Framework (ODF) for Canada.
Lee DK; Wong B
J Popul Ther Clin Pharmacol; 2014; 21(1):e42-6. PubMed ID: 24671833
[TBL] [Abstract][Full Text] [Related]
8. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.
Clarke JT
CMAJ; 2006 Jan; 174(2):189-90. PubMed ID: 16415465
[No Abstract] [Full Text] [Related]
9. Orphan drugs: Indian perspective.
Kumar H; Sarma P; Medhi B
Indian J Pharmacol; 2017; 49(4):267-269. PubMed ID: 29326485
[No Abstract] [Full Text] [Related]
10. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
Picavet E; Cassiman D; Pinxten W; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
[TBL] [Abstract][Full Text] [Related]
11. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
[TBL] [Abstract][Full Text] [Related]
12. The impact of orphan drug policies in treating rare diseases.
Weerasooriya SU
Health Info Libr J; 2019 Jun; 36(2):179-184. PubMed ID: 30933412
[TBL] [Abstract][Full Text] [Related]
13. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
14. Defining orphan conditions in the context of the European orphan regulation: challenges and evolution.
O'Connor DJ; Sheean ME; Hofer MP; Tsigkos S; Mariz S; Fregonese L; Larsson K; Hivert V; Westermark K; Naumann-Winter F; Stoyanova-Beninska V; Barišić I; Capovilla G; Magrelli A; Sepodes B
Nat Rev Drug Discov; 2019 Jul; 18(7):479-480. PubMed ID: 30940922
[No Abstract] [Full Text] [Related]
15. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
Herder M
Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
[TBL] [Abstract][Full Text] [Related]
16. [Orphan diseases, rare diseases, time to get mobilised].
Cordier JF
Rev Prat; 2006 Jan; 56(2):123-4. PubMed ID: 16584035
[No Abstract] [Full Text] [Related]
17. Policy alternatives for treatments for rare diseases.
Panju AH; Bell CM
CMAJ; 2010 Nov; 182(17):E787-92. PubMed ID: 20624867
[No Abstract] [Full Text] [Related]
18. Neuromuscular disorders: orphan diseases deserve attention.
de Visser M
Lancet Neurol; 2006 Jan; 5(1):13-4. PubMed ID: 16361013
[No Abstract] [Full Text] [Related]
19. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
20. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
